Table 3. Therapeutic response of patients and PDTX models.

Case	Stage	Differentiation	Lauren	HER2 expression	Regimen	Clinical response of patients	Concordancea
093	IV	Poor	Diffuse	Positive	XELOX+Trastuzumab	PR	Yes
098	IV	Well	Intestinal	Positive	S-1+Trastuzumab	SD	Yes
115	IV	Moderate	Intestinal	Positive	XELOX+Trastuzumab	PR	Yes
144	IV	Moderate	Intestinal	Positive	XELOX	SD	No
156	IV	Moderate	Intestinal	Negative	DCF	Increased SD	Yes

Note: PR, partial response; SD, stable disease;

^aconcordance: concordance of therapeutic response between patients and PDTX models.